BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...Plus ESMO data from Amgen, J&J, AstraZeneca and BMS By Lauren Martz, senior editor New data...
...of data presented this weekend at ESMO, including several readouts on next generation bispecific antibodies from Amgen...
...nivolumab (Generic), Opdivo (Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Amgen...
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

...“Siolta: Seeding the Microbiome”).Lilly, Amgen mAb manufacturing dealEli Lilly and Co. (NYSE:LLY) has partnered with Amgen...
...TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 BC Staff Siolta Therapeutics Inc. Eli Lilly and Co. Amgen...
BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...By Lauren Martz, Senior Editor Amgen’s leading KRAS...
...of Medical Oncology Virtual Congress on Sunday, Amgen...
...54% ORR and 100% disease control rate Amgen...
BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...companies will share the costs. MRTX849 and other G12C inhibitors, including frontrunner sotorasib (AMG 510) from Amgen...
...NASDAQ:AGN), work by locking the mutant form of the protein in an inactive state (see “Amgen...
...– Src homology protein tyrosine phosphatase 2SOS1 – Sons of sevenless homolog 1 Lauren Martz Mirati Therapeutics Inc. Amgen...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...quickly than a stand-alone protocol.” Elliott Levy, Amgen...
...drug developers.Elliott Levy, SVP global development at Amgen...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

...and interest in sharing grows.” Jules Desmond, Amgen...
...and infrastructure meet requisite data privacy and protections.Amgen...
...parallel with changing attitudes to data sharing. Amgen’s...
BioCentury | Sep 7, 2020
Product Development

Covert disease surveillance capacity needed to detect future pandemics, says Gottlieb: a BioCentury audio interview

...the CEOs, they all described pretty challenging circumstances, until I got to Bob Bradway of Amgen...
BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change

...development director, oncology and clinical development at Amgen...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

...HR=1.17; 95% CI: 1.01, 1.36).Darbepoetin alfa, which Amgen...
BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

...Staff Writer Mylan, Biocon launch long-acting insulin biosimilar in U.S.Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON...
...in adults with Type II diabetes and adults and children with Type I diabetes (see “Biocon...
...Dow Jones Amgen Inc. (NASDAQ:AMGN) became the first biotech to join the Dow Jones Industrial Average. Amgen’s...
Items per page:
1 - 10 of 7064